litlas
Log inCreate account

John Radford

Active 1988–2025

141
Papers
25,099
Citations
88
h-index
135
i10-index

Citations

Citations per year for John Radford1989: 3 citations1990: 2 citations1991: 7 citations1992: 4 citations1993: 11 citations1994: 7 citations1995: 17 citations1996: 14 citations1997: 23 citations1998: 19 citations1999: 18 citations2000: 52 citations2001: 85 citations2002: 91 citations2003: 85 citations2004: 98 citations2005: 142 citations2006: 96 citations2007: 114 citations2008: 115 citations2009: 128 citations2010: 139 citations2011: 146 citations2012: 115 citations2013: 123 citations2014: 157 citations2015: 154 citations2016: 144 citations2017: 169 citations2018: 196 citations2019: 566 citations2020: 707 citations2021: 689 citations2022: 668 citations2023: 411 citations2024: 686 citations2025: 283 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,330 citing papers, 26% of this breakdownUnited Kingdom: 738 citing papers, 8.2% of this breakdownGermany: 567 citing papers, 6.3% of this breakdownFrance: 538 citing papers, 6% of this breakdownChina: 524 citing papers, 5.8% of this breakdownItaly: 517 citing papers, 5.8% of this breakdownNetherlands: 341 citing papers, 3.8% of this breakdownCanada: 340 citing papers, 3.8% of this breakdownAustralia: 282 citing papers, 3.1% of this breakdownSwitzerland: 280 citing papers, 3.1% of this breakdownSpain: 274 citing papers, 3.1% of this breakdownBelgium: 226 citing papers, 2.5% of this breakdown
0%26%Other 22.5%

Institutions

Fields

  • Medicine84.2%
  • Biochemistry, Genetics and Molecular Biology8.7%
  • Immunology and Microbiology2.4%
  • Dentistry0.9%
  • Materials Science0.9%
  • Engineering0.7%
  • Other2.2%

Topics

  • Lymphoma Diagnosis and Treatment15.4%
  • CAR-T cell therapy research6.7%
  • Chronic Lymphocytic Leukemia Research6%
  • CNS Lymphoma Diagnosis and Treatment3.5%
  • Viral-associated cancers and disorders3.1%
  • Cancer Immunotherapy and Biomarkers2.6%
  • Other62.7%

Coauthors

All papers

Open in search
  1. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial

    Authors: Franck Morschhauser, Hervé Tilly, Aristeidis Chaidos, Pam McKay, Tycel Phillips, Sarit Assouline, Connie Lee Batlevi, Phillip L. Campbell, Vincent Ribrag, Gandhi Damaj, Michael Dickinson, Wojciech Jurczak, Maciej Kazmierczak, Stephen Opat, John Radford, Anna Schmitt, Jay Yang, Jennifer Whalen, Shefali Agarwal, Deyaa Adib, Gilles Salles - The Lancet Oncology 2020 cited by 587

  2. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

    Authors: Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, Kirit M. Ardeshna, Mehdi Hamadani, Brian Hess, Brad S. Kahl, John Radford, Melhem Solh, Anastasios Stathis, Pier Luigi Zinzani, Karin Havenith, Jay Feingold, Shui He, Yajuan Qin, David Ungar, Xiaoyan Zhang, Carmelo Carlo‐Stella - The Lancet Oncology 2021 cited by 417

  3. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

    Authors: Michael Wang, Simon Rule, Peter Martin, André Goy, Rebecca Auer, Brad S. Kahl, Wojciech Jurczak, Ranjana H. Advani, Jorge Romaguera, Michael E. Williams, Jacqueline C. Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Martin Dreyling, W Wiktor-Jędrzejczak, Peter Johnson, Stephen E. Spurgeon, Lei Li, Liang Zhang, Kate J. Newberry, Zhishuo Ou, Nancy Cheng, Bingliang Fang, Jesse McGreivy, Fong Clow, Joseph J. Buggy, Betty Chang, Darrin M. Beaupre, Lori Kunkel, Kristie A. Blum - New England Journal of Medicine 2013 cited by 1,687

  4. Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

    Authors: Stephen M. Ansell, John Radford, Joseph M. Connors, Monika Długosz‐Danecka, Won-Seog Kim, Andrea Gallamini, Radhakrishnan Ramchandren, Jonathan W. Friedberg, Ranjana H. Advani, Martin Hutchings, Andrew M. Evens, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Hyeon‐Seok Eom, Jeremy S. Abramson, Cassie Dong, Frank Campana, Keenan Fenton, Markus Puhlmann, David J. Straus - New England Journal of Medicine 2022 cited by 328

  5. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

    Authors: Joseph M. Connors, Wojciech Jurczak, David J. Straus, Stephen M. Ansell, Won S. Kim, Andrea Gallamini, Anas Younes, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech‐Marańda, Yasuhiro Oki, Tatyana Feldman, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Jan Walewski, Robert Chen, Radhakrishnan Ramchandren, Pier Luigi Zinzani, David Cunningham, András Rosta, Neil C. Josephson, Eric Song, Jessica Sachs, Rachael Liu, Hina Jolin, Dirk Huebner, John Radford - New England Journal of Medicine 2017 cited by 764

  6. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

    Authors: Robert Chen, Pier Luigi Zinzani, Michelle A. Fanale, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Yinghua Zhang, Alejandro D. Ricart, Arun Balakumaran, Craig H. Moskowitz, for the KEYNOTE-087 - Journal of Clinical Oncology 2017 cited by 985

  7. Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I–Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial

    Authors: Peter Henriksen, Peter S Hall, Iain R. Macpherson, Shruti Joshi, Trisha Singh, Morag MacLean, Steff Lewis, Aryelly Rodríguez, Alex Fletcher, Russell J. Everett, Harriet Stavert, Angus Broom, Lois Eddie, Lorraine Primrose, Heather McVicars, Pam McKay, Annabel Borley, Clare Rowntree, Simon Lord, Graham P. Collins, John Radford, Amy Guppy, Michelle C. Williams, Alan G. Japp, John R. Payne, David E. Newby, Nicholas L. Mills, Olga Oikonomidou, Ninian N. Lang - Circulation 2023 cited by 73

  8. Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin’s Lymphoma

    Authors: Peter Johnson, Massimo Federico, Amy A. Kirkwood, Alexander Fosså, Leanne Berkahn, Angelo Michele Carella, Francesco d’Amore, Gunilla Enblad, Antonella Franceschetto, Michael Fulham, Stefano Luminari, Michael O'Doherty, Pip Patrick, Thomas A. Roberts, Gamal Sidra, Lindsey Stevens, Paul Smith, Judith Trotman, Zaid Viney, John Radford, Sally F. Barrington - New England Journal of Medicine 2016 cited by 798

  9. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

    Authors: David Cunningham, Eliza A. Hawkes, Andrew Jack, Wendi Qian, Paul Smith, Paul Mouncey, Christopher Pocock, Kirit M. Ardeshna, John Radford, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, Joanna Gambell, David C. Linch - The Lancet 2013 cited by 556

  10. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

    Authors: Mehdi Hamadani, John Radford, Carmelo Carlo‐Stella, Paolo F. Caimi, Erin Reid, Owen A. O’Connor, Jay Feingold, Kirit M. Ardeshna, William Townsend, Melhem Solh, Leonard T. Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S. Kahl - Blood 2020 cited by 169

  11. Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma

    Authors: Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz - Blood 2023 cited by 105

  12. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

    Authors: Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Jianxin Lin, Eunhee Kim, Akash Nahar, Arun Balakumaran, Craig H. Moskowitz - Blood 2019 cited by 329

  13. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study

    Authors: Éric Van Den Neste, Norbert Schmitz, Nicolas Mounier, Devinder Gill, David C. Linch, Marek Trněný, Nöel Milpied, John Radford, Nicolas Ketterer, Ofer Shpilberg, Ulrich Dührsen, Dávid Ma, Josette Brière, Catherine Thiéblemont, Gilles Salles, Craig H. Moskowitz, B. Glaß, Christian Gisselbrecht - Bone Marrow Transplantation 2015 cited by 316

  14. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

    Authors: David J. Straus, Monika Długosz‐Danecka, Joseph M. Connors, Sergey Alekseev, Árpád Illés, Marco Picardi, Ewa Lech‐Marańda, Tatyana Feldman, Piotr Smolewski, Kerry J. Savage, Nancy L. Bartlett, Jan Walewski, Radhakrishnan Ramchandren, Pier Luigi Zinzani, Martin Hutchings, Javier Muñoz, Hun Ju Lee, Won Seog Kim, Ranjana H. Advani, Stephen M. Ansell, Anas Younes, Andrea Gallamini, Rachael Liu, Meredith Little, Keenan Fenton, Michelle A. Fanale, John Radford - The Lancet Haematology 2021 cited by 160

  15. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

    Authors: Mahmoud Elsawy, Julio C. Chávez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, Kelly Davison, Jakob Rudzki, Saurabh Dahiya, Kathleen Dorritie, Samantha Jaglowski, John Radford, Franck Morschhauser, David Cunningham, Alejandro Martı́n, Dimitrios Tzachanis, Matthew L. Ulrickson, Reem Karmali, Natasha Kekre, Catherine Thiéblemont, Gunilla Enblad, Peter Dreger, Ram Malladi, Namita Joshi, Wei‐Jhih Wang, Caitlyn T. Solem, Julia Thornton Snider, Paul Cheng, Christina To, Marie José Kersten - Blood 2022 cited by 75

  16. Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin’s Lymphoma

    Authors: John Radford, Tim Illidge, Nicholas Counsell, Barry W. Hancock, Ruth Pettengell, Peter Johnson, Jennie Wimperis, Dominic Culligan, Bilyana Popova, Paul Smith, Andrew McMillan, Alison Brownell, Anton Kruger, Andrew Lister, Peter Hoskin, Michael O’Doherty, Sally F. Barrington - New England Journal of Medicine 2015 cited by 750

  17. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

    Authors: Michael Wang, Kristie A. Blum, Peter Martin, André Goy, Rebecca Auer, Brad S. Kahl, Wojciech Jurczak, Ranjana H. Advani, Jorge Romaguera, Michael E. Williams, Jacqueline C. Barrientos, Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Martin Dreyling, W Wiktor-Jędrzejczak, Peter Johnson, Stephen E. Spurgeon, Liang Zhang, Linda Baher, Mei Cheng, Dana Lee, Darrin M. Beaupre, Simon Rule - Blood 2015 cited by 402

  18. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma

    Authors: Ian Judson, John Radford, Martin Harris, Jean‐Yves Blay, Q. van Hoesel, Axel Le Cesne, A.T. van Oosterom, M. Clemons, Claus Kamby, C. Hermans, J Whittaker, Eugenio Donato Di Paola, Jaco J. Verweij, Søren Nielsen - European Journal of Cancer 2001 cited by 391

  19. Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study

    Authors: Mehdi Hamadani, Graham P. Collins, Paolo F. Caimi, Felipe Samaniego, Alexander I. Spira, Andrew Davies, John Radford, Tobias Menne, Anand B. Karnad, Jasmine Zain, Paul Fields, Karin Havenith, Hans G. Cruz, Shui He, Joseph Boni, Jay Feingold, Jens Wuerthner, Steven M. Horwitz - The Lancet Haematology 2021 cited by 86

  20. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study

    Authors: Gustaaf W. van Imhoff, Andrew McMillan, Matthew J. Matasar, John Radford, Kirit M. Ardeshna, Kazimierz Kuliczkowski, Won-Seog Kim, Xiaonan Hong, Jette Soenderskov Goerloev, Andrew Davies, María Dolores Caballero Barrigón, Michinori Ogura, Sirpa Leppä, Michael Fennessy, Qiming Liao, Bronno van der Holt, Steen Lisby, Anton Hagenbeek - Journal of Clinical Oncology 2017 cited by 237

  21. Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study

    Authors: Paola Ghione, M. Lia Palomba, Hervé Ghesquières, Sabela Bobillo, Anik R. Patel, Myrna Nahas, Steve Kanters, Kevin Deighton, Anthony J. Hatswell, Long Ma, Eve H. Limbrick‐Oldfield, Julia Thornton Snider, Sally W. Wade, Maria Teresa Riberio, John Radford, Sara Beygi, John G. Gribben - Haematologica 2022 cited by 48

  22. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study

    Authors: Paolo F. Caimi, Weiyun Z. Ai, Juan Pablo Alderuccio, Kirit M. Ardeshna, Mehdi Hamadani, Brian Hess, Brad S. Kahl, John Radford, Melhem Solh, Anastasios Stathis, Pier Luigi Zinzani, Ying Wang, Yajuan Qin, Luqiang Wang, Zhiying Cindy Xu, Carmelo Carlo‐Stella - Haematologica 2023 cited by 34

  23. Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

    Authors: Elizabeth L. Budde, Nancy L. Bartlett, Pratyush Giri, Stephen J. Schuster, Sarit Assouline, Sung‐Soo Yoon, Keith Fay, Matthew J. Matasar, Norma C. Gutiérrez, Paula Marlton, Martin Dreyling, Dok Hyun Yoon, Georg Heß, John Radford, Volker Wiebking, Shen Yin, Eva Cybulski, David C. Turner, Huang Huang, Mingzhu Zhou, Elicia Penuel, Michael C. Wei, Laurie H. Sehn - Blood 2022 cited by 23

  24. Silver diamine fluoride for managing carious lesions: an umbrella review

    Authors: Nassar Seifo, Heather Cassie, John Radford, Nicola Innes - BMC Oral Health 2019 cited by 220